背景:我们旨在评估超声引导下高强度聚焦超声(USgHIFU)治疗子宫肌瘤的女性卵巢储备和生活质量的变化。
方法:在这项单中心前瞻性研究中,纳入2018年10月至2021年11月接受USgHIFU治疗的69例子宫肌瘤患者.纤维体积,抗苗勒管激素(AMH)水平,子宫肌瘤症状评分,并对USgHIFU治疗前和治疗后1、3、6个月的子宫肌瘤症状和生活质量(UFS-QOL)问卷评分进行分析。AMH水平与年龄的相关性,纤维瘤类型,和肌瘤位置进行了评估。
结果:分析了本研究中69例患者中54例的数据。基线和USgHIFU治疗后1个月和6个月的UFS-QOL评分为70(50.75-87.50),57(44.75-80.00),和52(40.75-69.00)分,分别(p<0.001)。与1个月的随访相比,3个月的肌瘤体积减少率显着增加(p<0.001),在3个月和6个月的随访之间没有观察到显着变化(p>0.99)。治疗前和治疗后1、3和6个月的平均AMH水平为1.22(0.16-3.28)ng/ml,1.12(0.18-2.52)ng/ml,1.15(0.19-2.08)ng/ml和1.18(0.36-2.43)ng/ml,分别(p=0.2)。多元线性回归分析显示年龄与AMH水平独立相关。
结论:USgHIFU治疗子宫肌瘤能显著改善患者生活质量,对卵巢功能的影响最小。
BACKGROUND: We aimed to evaluate changes in ovarian reserve and quality of life in women treated with ultrasound-guided high-intensity focused ultrasound (USgHIFU) for uterine fibroids.
METHODS: In this single-center prospective study, a total of 69 patients with uterine fibroids treated with USgHIFU from October 2018 to November 2021 were enrolled. Fibroid volume, anti-Müllerian hormone (AMH) levels, uterine fibroid symptom scores, and uterine fibroid symptoms and quality of life (UFS-QOL) questionnaire scores before and 1, 3, and 6 months after USgHIFU treatment were analyzed. Correlations between AMH levels and age, fibroid type, and fibroid location were assessed.
RESULTS: Data from 54 of the 69 patients included in the present study were analyzed. The UFS-QOL scores at baseline and at 1 month and 6 months after USgHIFU treatment were 70 (50.75-87.50), 57 (44.75-80.00), and 52 (40.75-69.00) points, respectively (p < 0.001). The rate of fibroid volume reduction increased significantly at the 3-month follow-up compared with the 1-month follow-up (p < 0.001), and no significant change was observed between the 3-month and 6-month follow-ups (p > 0.99). The median AMH levels before and at 1, 3 and 6 months after treatment were 1.22 (0.16-3.28) ng/ml, 1.12 (0.18-2.52) ng/ml, 1.15 (0.19-2.08) ng/ml and 1.18 (0.36-2.43) ng/ml, respectively (p = 0.2). Multivariate linear regression analyses revealed that age was independently associated with AMH levels.
CONCLUSIONS: USgHIFU treatment for uterine fibroids can significantly improve quality of life with minimal adverse effects on ovarian function.